High intake of the artificial sweetener sucralose may reduce the efficacy of ICIs in patients with cancer, data suggest.

Research links environmental exposures to CKD development and progression. Here’s what clinicians and patients need to know.

Prevalence of glycemic control and use of diabetes technology lowest in Hispanic, non-Hispanic Black, Medicaid-insured.

Stereotactic ablative body radiation therapy (SABR) is actively being explored for patients with renal cell carcinoma (RCC).

Findings seen across body mass index groups. (HealthDay News) — Metformin use is associated with lower risks for dementia and all-cause mortality across body mass index (BMI) groups in patients ...

Hispanic, Black non-Hispanic, White non-Hispanic adults more likely to use GLP-1 RA injectables than Asian non-Hispanics. (HealthDay News) — In 2024, 26.5 percent of adults with diagnosed ...

Pembrolizumab plus lenvatinib is currently a standard of care for clear-cell renal cell carcinoma (RCC), so investigators assessed the combination for non-clear-cell RCC.

Research teams investigated the association between hemoglobin levels and cognitive impairment in patients with chronic kidney disease (CKD) or end-stage (ESKD).

There is decreased risk for MACE and all-cause mortality in dialysis-dependent patients with ASCVD who are treated with statins.

The FDA has approved an expanded indication of the IV formulation of Avtozma to include the treatment of CRS in patients 2 years of age and older.